Published in AIDS Weekly, November 23rd, 1998
The vaccine consisted of autologous melanoma cells transfected with human granulocyte-macrophage colony-stimulating factor (GM-CSF) and then lethally irradiated.
"Metastatic lesions resected after vaccination were densely infiltrated with T lymphocytes and plasma cells and showed extensive tumor destruction (at least 80 percent), fibrosis, and edema," wrote Robert Soiffer and Glenn Dranoff of Harvard Medical School, Boston, Massachusetts, and colleagues.
Soiffer et al. reported their findings in the journal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1998-11-23)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.